CN104202977A - 小分子glp1r激动剂的三(羟甲基)氨基甲烷盐及其药物组合物和用途 - Google Patents

小分子glp1r激动剂的三(羟甲基)氨基甲烷盐及其药物组合物和用途 Download PDF

Info

Publication number
CN104202977A
CN104202977A CN201380015508.2A CN201380015508A CN104202977A CN 104202977 A CN104202977 A CN 104202977A CN 201380015508 A CN201380015508 A CN 201380015508A CN 104202977 A CN104202977 A CN 104202977A
Authority
CN
China
Prior art keywords
solid composite
salt
tris
odaad1
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380015508.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·阿尔玛里戈
D·R·珀里斯蒂
E·本杰明
H·艾尔阿博德劳伊
S·P·萨霍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
Trans Tech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc filed Critical Trans Tech Pharma Inc
Publication of CN104202977A publication Critical patent/CN104202977A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380015508.2A 2012-03-22 2013-03-20 小分子glp1r激动剂的三(羟甲基)氨基甲烷盐及其药物组合物和用途 Pending CN104202977A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614265P 2012-03-22 2012-03-22
US61/614,265 2012-03-22
PCT/US2013/033091 WO2013142569A1 (en) 2012-03-22 2013-03-20 Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
CN104202977A true CN104202977A (zh) 2014-12-10

Family

ID=49223316

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380015508.2A Pending CN104202977A (zh) 2012-03-22 2013-03-20 小分子glp1r激动剂的三(羟甲基)氨基甲烷盐及其药物组合物和用途

Country Status (16)

Country Link
US (1) US9198901B2 (enExample)
EP (1) EP2854526B1 (enExample)
JP (1) JP2015510947A (enExample)
KR (1) KR102158992B1 (enExample)
CN (1) CN104202977A (enExample)
AU (1) AU2013235167B2 (enExample)
CA (1) CA2868033A1 (enExample)
EA (1) EA201491749A1 (enExample)
ES (1) ES2674951T3 (enExample)
HK (1) HK1199371A1 (enExample)
IL (1) IL234615B (enExample)
IN (1) IN2014DN07867A (enExample)
MX (1) MX352804B (enExample)
NZ (1) NZ629203A (enExample)
SG (1) SG11201405353VA (enExample)
WO (1) WO2013142569A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021196949A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
WO2021196951A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217165A1 (en) * 2018-05-08 2019-11-14 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1225580A (zh) * 1996-05-20 1999-08-11 G·D·瑟尔公司 钾、钠和三羟甲基氨基甲烷噁丙秦盐药物配方
CN1351491A (zh) * 1999-05-25 2002-05-29 史密丝克莱恩比彻姆公司 顺－[4－氰基－4－(3－环戊氧基－4－甲氧苯基)环己烷－1－羧酸]的盐类
CN101959405A (zh) * 2008-03-07 2011-01-26 转化技术制药公司 治疗糖尿病的氧杂二氮杂蒽化合物
TW201114422A (en) * 2009-09-11 2011-05-01 Transtech Pharma Inc Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
CN102056897A (zh) * 2008-06-05 2011-05-11 旭化成制药株式会社 磺酰胺化合物及其用途
CN102245606A (zh) * 2008-12-08 2011-11-16 葛兰素史密斯克莱有限责任公司 新化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363913A2 (en) * 2001-02-05 2003-11-26 Dr. Reddy's Laboratories Ltd. Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
EP1439834A1 (en) * 2001-10-30 2004-07-28 Applied Research Systems ARS Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
BRPI0409501A (pt) * 2003-04-18 2006-04-18 Incyte San Diego Inc compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças
WO2009123241A1 (ja) * 2008-03-31 2009-10-08 株式会社レナサイエンス プラスミノーゲンアクチベーターインヒビター－１阻害剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1225580A (zh) * 1996-05-20 1999-08-11 G·D·瑟尔公司 钾、钠和三羟甲基氨基甲烷噁丙秦盐药物配方
CN1351491A (zh) * 1999-05-25 2002-05-29 史密丝克莱恩比彻姆公司 顺－[4－氰基－4－(3－环戊氧基－4－甲氧苯基)环己烷－1－羧酸]的盐类
CN101959405A (zh) * 2008-03-07 2011-01-26 转化技术制药公司 治疗糖尿病的氧杂二氮杂蒽化合物
CN102056897A (zh) * 2008-06-05 2011-05-11 旭化成制药株式会社 磺酰胺化合物及其用途
CN102245606A (zh) * 2008-12-08 2011-11-16 葛兰素史密斯克莱有限责任公司 新化合物
TW201114422A (en) * 2009-09-11 2011-05-01 Transtech Pharma Inc Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021196949A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
WO2021196951A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
CN115315426A (zh) * 2020-04-01 2022-11-08 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
CN115461344A (zh) * 2020-04-01 2022-12-09 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
CN115315426B (zh) * 2020-04-01 2023-12-12 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
CN115461344B (zh) * 2020-04-01 2024-01-12 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
US12421245B2 (en) 2020-04-01 2025-09-23 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of GLP1 receptor agonist, and preparation method therefor
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor

Also Published As

Publication number Publication date
EP2854526A4 (en) 2016-02-24
SG11201405353VA (en) 2014-09-26
CA2868033A1 (en) 2013-09-26
EA201491749A1 (ru) 2015-01-30
AU2013235167A1 (en) 2014-09-18
US9198901B2 (en) 2015-12-01
AU2013235167B2 (en) 2017-03-30
ES2674951T3 (es) 2018-07-05
HK1199371A1 (en) 2015-07-03
MX2014010366A (es) 2015-05-15
IN2014DN07867A (enExample) 2015-04-24
MX352804B (es) 2017-12-08
KR102158992B1 (ko) 2020-09-23
KR20140138758A (ko) 2014-12-04
JP2015510947A (ja) 2015-04-13
NZ629203A (en) 2015-12-24
WO2013142569A1 (en) 2013-09-26
EP2854526B1 (en) 2018-04-25
IL234615B (en) 2018-02-28
ES2674951T8 (es) 2018-08-23
US20150005339A1 (en) 2015-01-01
EP2854526A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
US20250288681A1 (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
JP2012501971A (ja) 共結晶および共結晶を含む薬学的処方物
JP2021535893A (ja) グルコキナーゼ活性化剤およびｄｐｐ−ｉｖ阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用
US9198901B2 (en) Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof
CN101677961B (zh) 包含苯并咪唑-7-羧酸酯衍生物和pH控制剂的固体药物组合物
CN101686930A (zh) 新颖的药物组合物
TW201302198A (zh) 含有納布啡（ｎａｌｂｕｐｈｉｎｅ）之藥學組成物及其用途
JP2013508370A (ja) ジペプチジルペプチダーゼ−４阻害剤とピオグリタゾンとの組み合わせの医薬組成物
JP2022545862A (ja) Ｇｌｐ－１ペプチドを含む錠剤を生成するためのプロセス
US20110064806A1 (en) Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
CA2896308A1 (en) Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
CN102274223B (zh) 含替米沙坦和氨氯地平的复方制剂
JP5713990B2 (ja) ２型糖尿病治療用の医薬組成物
CN1276724A (zh) 依普沙坦精氨酰电荷中和复合体及其制备过程和制剂
WO2025218797A1 (zh) 一种胶囊或固体制剂及其应用
HK40044644A (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
HK1158542A (en) Co-crystals and pharmaceutical formulations comprising the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1199371

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: North Carolina

Applicant after: vTv Therapeutics LLC

Address before: North Carolina

Applicant before: TRANSTECH PHARMA, Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: TRANSFORMATION TECHNOLOGY PHARMA, LLC TO: VTV THERAPEUTICS LLC

Free format text: CORRECT: ADDRESS; FROM:

C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: North Carolina

Applicant after: VTVX Holdings I LLC

Address before: North Carolina

Applicant before: VTV THERAPEUTICS LLC

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20151130

Address after: North Carolina

Applicant after: vTv Therapeutics LLC

Address before: North Carolina

Applicant before: VTVX Holdings I LLC

RJ01 Rejection of invention patent application after publication

Application publication date: 20141210

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1199371

Country of ref document: HK